Same Drug, Two Prices: Why The Higher Price Prevails

[ad_1] The way medicines are paid for in the U.S. has become so convoluted that some drugmakers are setting two prices for the same drug—and many health plans are choosing…

Obesity Drug Demand Outstrips Supply

[ad_1] Eli Lilly’s blockbuster diabetes medication Mounjaro is expected to receive Food and Drug Administration approval as an obesity treatment before the end of the year, which would lead to…

Never Mind Covid, Investors Want a Pfizer Obesity Pill

[ad_1] Some of this year’s best performers in the healthcare sector are companies expected to profit from the anti-obesity drug craze, with Eli Lilly and Novo Nordisk shares both up…

MORNING BID EUROPE-Markets hold their nerve amid Mid East trouble

[ad_1] A look at the day ahead in European and global markets from Wayne Cole. It’s been a cautious start in Asian markets as Israeli troops backed by tanks pressed…

Ozempic Maker Novo Nordisk Has a Weight Problem

[ad_1] Oct. 23, 2023 11:39 am ET The company behind diabetes and obesity phenomena Ozempic and Wegovy is overweight. Novo Nordisk became Europe’s most valuable company last month, overtaking luxury…

Ozempic Boom Is an Opportunity for Health Insurers

[ad_1] You would think a new class of high-price weight loss drugs taken by millions of Americans would be a problem for health insurers. After all, they ultimately foot the…

WSJ News Exclusive | The Next Hot Obesity Drug Won’t Be Approved for Years. Online Sellers Hawk It Anyway.

[ad_1] Eli Lilly’s retatrutide will be in clinical trials for the next three years, but knockoff versions already abound. [ad_2] Source link

Stocks Clinch Four-Day Winning Streak

[ad_1] Long-term Treasury yields continued to ease. [ad_2] Source link

America’s Food Giants Confront the Ozempic Era

[ad_1] Nearly 7% of the U.S. population is projected to be on weight-loss drugs in 2035. [ad_2] Source link

Eli Lilly Diabetes, Obesity Head Mike Mason to Retire

[ad_1] The head of Eli Lilly’s burgeoning diabetes and obesity franchise is retiring at the end of the year. Mike Mason is leaving after 34 years with the company. [ad_2]…